Archive · 8 Sep 2026
Pfizer Shares Fall as Novartis Buys Minipress Trademarks
Pfizer Ltd said its Minipress XL product is being discontinued in India.
Its shares fell to their lowest level in 52 weeks.
Pfizer Ltd will receive about Rs 131.38 crore from Pfizer Inc, USA, as part of the discontinuation.
Novartis India agreed to buy the Minipress and Minipres trademarks from Pfizer companies.
The deal is worth about Rs 1,250 crore.
After the announcement, Novartis India shares rose nearly 13% to a 52-week high.
Minipress XL is used mainly for high blood pressure and some urinary symptoms.
The product made Rs 228.6 crore in revenue based on the cited July 2026 data.
Pfizer Ltd shares hit a 52-week low after Minipress XL was discontinued.
Pfizer Ltd will receive a $13.9 million lump-sum payment from Pfizer Inc, USA.
Novartis India shares rose 12.87% to a 52-week high of Rs 1,850.95.
Novartis India agreed to acquire the Minipress and Minipres trademarks for approximately Rs 1,250 crore.
Minipress XL generated Rs 228.6 crore in revenue and had a 6.3% four-year CAGR, according to cited IQVIA data.
- Who
- Pfizer Ltd, Pfizer Inc., Pfizer Products Inc., and Novartis India are involved.
- What
- Novartis India is acquiring the Minipress and Minipres trademarks and related intellectual property, while Pfizer Ltd is discontinuing Minipress XL.
- When
- The reports cite IQVIA MAT July 2026 data; the filings said signing and closing would occur simultaneously.
- Where
- The trademarks are registered in India, and the transaction involves Pfizer entities in the United States and Novartis India.
- Why
- The trademark acquisition is connected to the discontinuation of Minipress XL by Pfizer Ltd.
- Pfizer payment
- $13.9 million, or approximately Rs 131.38 crore
- Novartis transaction value
- Approximately Rs 1,250 crore
- Novartis India share move
- Rose 12.87% to Rs 1,850.95
- Pfizer share move
- Pfizer Ltd shares hit a 52-week low
- Product
- Minipress XL, containing prazosin
- Reported revenue
- Rs 228.6 crore, according to IQVIA MAT July 2026 data
- Four-year CAGR
- 6.3%